cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4401087
title: Dataset related to article "Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases"

description: This record contains raw data related to article "Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases" Lymph nodes are common sites of oligometastases for several primaries. Stereotactic body radiation therapy (SBRT) represents an effective treatment but no consensus exists regarding dose and fractionation. Aim of this trial was to evaluate safety and efficacy of high-dose SBRT. We included patients with 1 to 3 lymph node metastases. Primary end-point was safety, while secondary end-points were in-field local control (LC), out-field lymph nodal progression free survival (LPFS), distant metastasis free survival (DMFS), progression free survival (PFS) and overall survival (OS). 64 lesions in 52 patients were treated from 2015 to 2019. Most common primary tumor was genitourinary cancer (75%), in particular prostate cancer (65.4%). With a median follow-up of 24.4 months (range 3-49), treatment was very well tolerated, with only 4 (7.7%) patients reporting acute side effects, all classified as grade 1, in the form of pain, fatigue, nocturia and dysuria. No toxicity ≥ grade 2 were reported. Rates of LC at 1, 2 and 3 years were 97.9%, 82.1% and 82.1%. Male sex (HR 0.12, p value 0.014) was associated with improved LC. LPFS at 1, 2 and 3 years were 69.6%, 49.6% and 46.1%, respectively, and DMFS was 81.74%, 67.5% and 58.5%, respectively. Presence of lesions in other organs was correlated with inferior DMFS (HR 3.82, p = 0.042). PFS at 1, 2 and 3 years were 67.4%, 42.4% and 31.86%, respectively. OS at 1, 2 and 3 years were 97.3%, 94.2%, 84%, respectively and significantly correlated with in-field recurrence (HR 8.72, p = 0.000). Our prospective trial confirms safety and efficacy of SBRT in the management of lymph node metastases. Registered Clinical trial NCT02570399.
DOI: 10.5281/zenodo.4384588
title: Dataset related to article "Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases"

description: This record contains raw data related to article "Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases" Lymph nodes are common sites of oligometastases for several primaries. Stereotactic body radiation therapy (SBRT) represents an effective treatment but no consensus exists regarding dose and fractionation. Aim of this trial was to evaluate safety and efficacy of high-dose SBRT. We included patients with 1 to 3 lymph node metastases. Primary end-point was safety, while secondary end-points were in-field local control (LC), out-field lymph nodal progression free survival (LPFS), distant metastasis free survival (DMFS), progression free survival (PFS) and overall survival (OS). 64 lesions in 52 patients were treated from 2015 to 2019. Most common primary tumor was genitourinary cancer (75%), in particular prostate cancer (65.4%). With a median follow-up of 24.4 months (range 3-49), treatment was very well tolerated, with only 4 (7.7%) patients reporting acute side effects, all classified as grade 1, in the form of pain, fatigue, nocturia and dysuria. No toxicity ≥ grade 2 were reported. Rates of LC at 1, 2 and 3 years were 97.9%, 82.1% and 82.1%. Male sex (HR 0.12, p value 0.014) was associated with improved LC. LPFS at 1, 2 and 3 years were 69.6%, 49.6% and 46.1%, respectively, and DMFS was 81.74%, 67.5% and 58.5%, respectively. Presence of lesions in other organs was correlated with inferior DMFS (HR 3.82, p = 0.042). PFS at 1, 2 and 3 years were 67.4%, 42.4% and 31.86%, respectively. OS at 1, 2 and 3 years were 97.3%, 94.2%, 84%, respectively and significantly correlated with in-field recurrence (HR 8.72, p = 0.000). Our prospective trial confirms safety and efficacy of SBRT in the management of lymph node metastases. Registered Clinical trial NCT02570399.
DOI: 10.5281/zenodo.4384589
title: Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases

description: Lymph nodes are common sites of oligometastases for several primaries. Stereotactic body radiation therapy (SBRT) represents an effective treatment but no consensus exists regarding dose and fractionation. Aim of this trial was to evaluate safety and efficacy of high-dose SBRT. We included patients with 1 to 3 lymph node metastases. Primary end-point was safety, while secondary end-points were in-field local control (LC), out-field lymph nodal progression free survival (LPFS), distant metastasis free survival (DMFS), progression free survival (PFS) and overall survival (OS). 64 lesions in 52 patients were treated from 2015 to 2019. Most common primary tumor was genitourinary cancer (75%), in particular prostate cancer (65.4%). With a median follow-up of 24.4 months (range 3-49), treatment was very well tolerated, with only 4 (7.7%) patients reporting acute side effects, all classified as grade 1, in the form of pain, fatigue, nocturia and dysuria. No toxicity ≥ grade 2 were reported. Rates of LC at 1, 2 and 3 years were 97.9%, 82.1% and 82.1%. Male sex (HR 0.12, p value 0.014) was associated with improved LC. LPFS at 1, 2 and 3 years were 69.6%, 49.6% and 46.1%, respectively, and DMFS was 81.74%, 67.5% and 58.5%, respectively. Presence of lesions in other organs was correlated with inferior DMFS (HR 3.82, p = 0.042). PFS at 1, 2 and 3 years were 67.4%, 42.4% and 31.86%, respectively. OS at 1, 2 and 3 years were 97.3%, 94.2%, 84%, respectively and significantly correlated with in-field recurrence (HR 8.72, p = 0.000). Our prospective trial confirms safety and efficacy of SBRT in the management of lymph node metastases. Registered Clinical trial NCT02570399.
DOI: 10.6084/m9.figshare.13198340
title: Linkage analysis of GspB glycosylated by GtfAB, Nss and Gly

description: Glycan linkage<b> </b>determination was carried out as service performed by the GlycoAnalytics Core center at the University of California, San Diego. In brief,<b> </b>Glycans were liberated from purified GST-SRR1 (glycosylated by GtfAB, Nss and Gly) by reductive beta elimination using base-borohydride treatment. The <i>O</i>-glycans were then purified and per-methylated according to the method of Ciucannu and Kerek. In brief, <i>O</i>-glycans were dried and dissolved in anhydrous DMSO, followed by adding NaOH slurry in DMSO and methyl iodide. Per-methylated glycans were extracted by partitioning in water-chloroform mixture and the chloroform layer was dried and used for linkage analysis. The per-methylated glycans were hydrolyzed using 4N TFA at 100°C for 6 hr, followed by removal of the acid, reduced with sodium borodeuteride and acetylated to generate the per-methylated alditol acetate (PMAA) derivative, which was then analyzed by GC-MS using Restek-5ms capillary column for inter-residue linkages. Identifications are achieved by using a combination of retention times and EI mass fragmentation pattern.
DOI: 10.6084/m9.figshare.13198340.v2
title: Linkage analysis of GspB glycosylated by GtfAB, Nss and Gly

description: Glycan linkage<b> </b>determination was carried out as service performed by the GlycoAnalytics Core center at the University of California, San Diego. In brief,<b> </b>Glycans were liberated from purified GST-SRR1 (glycosylated by GtfAB, Nss and Gly) by reductive beta elimination using base-borohydride treatment. The <i>O</i>-glycans were then purified and per-methylated according to the method of Ciucannu and Kerek. In brief, <i>O</i>-glycans were dried and dissolved in anhydrous DMSO, followed by adding NaOH slurry in DMSO and methyl iodide. Per-methylated glycans were extracted by partitioning in water-chloroform mixture and the chloroform layer was dried and used for linkage analysis. The per-methylated glycans were hydrolyzed using 4N TFA at 100°C for 6 hr, followed by removal of the acid, reduced with sodium borodeuteride and acetylated to generate the per-methylated alditol acetate (PMAA) derivative, which was then analyzed by GC-MS using Restek-5ms capillary column for inter-residue linkages. Identifications are achieved by using a combination of retention times and EI mass fragmentation pattern.
DOI: 10.6084/m9.figshare.13198340.v1
title: Linkage analysis of GspB glycosylated by GtfAB, Nss and Gly

description: Glycan linkage<b> </b>determination was carried out as service performed by the GlycoAnalytics Core center at the University of California, San Diego. In brief,<b> </b>Glycans were liberated from purified GST-SRR1 (glycosylated by GtfAB, Nss and Gly) by reductive beta elimination using base-borohydride treatment. The <i>O</i>-glycans were then purified and per-methylated according to the method of Ciucannu and Kerek. In brief, <i>O</i>-glycans were dried and dissolved in anhydrous DMSO, followed by adding NaOH slurry in DMSO and methyl iodide. Per-methylated glycans were extracted by partitioning in water-chloroform mixture and the chloroform layer was dried and used for linkage analysis. The per-methylated glycans were hydrolyzed using 4N TFA at 100°C for 6 hr, followed by removal of the acid, reduced with sodium borodeuteride and acetylated to generate the per-methylated alditol acetate (PMAA) derivative, which was then analyzed by GC-MS using Restek-5ms capillary column for inter-residue linkages. Identifications are achieved by using a combination of retention times and EI mass fragmentation pattern.
DOI: 10.5281/zenodo.4384602
title: Dataset related to article "Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"

description: This record contains raw data related to article “Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy" <strong>Introduction: </strong>Liver and lung are common sites of metastases from colorectal cancer (CRC). Stereotactic body radiation therapy (SBRT) represents a valid treatment, with high rates of local control (LC). In this study, we applied recursive partitioning model-based analysis (RPA) to define class risks for overall survival (OS) and progression free survival (PFS) in oligometastatic CRC patients. <strong>Materials and methods: </strong>In this monocentric analysis, we included patients with lung or liver metastases. Patients were candidate to SBRT if a maximum of 5 metastases. End points of the present analysis were LC, PFS, and OS. The binary classification tree approach with RPA was applied to stratify the patients into risk groups based on OS and PFS. <strong>Results: </strong>218 patients were treated with SBRT on 371 metastases. Majority of patients (56%) was treated on single lesion, followed by 2 (26.1%) and 3 lesions (14.7%). Median follow-up was 22.7 months. Rates of LC were 84.2% at 1 year and 73.8% at 3 years. Rates of PFS at 1 and 3 years were 42.2% and 14.9%, respectively. RPA identified 3 classes for PFS, according to age and number of metastases with 3-year PFS of 30.6%, 13.5% and 8.4%. Overall survival was 87.2% at 1 year, 51.9% at 3 years, and 36.8% at 5 years. RPA identified 3 nodes. Class 1 included patients with liver metastases (3-year OS 35.2%). Class 2 included patients with lung metastases and DFI ≤ 48 months (3-year OS 65%). Class 3 included patients with lung metastases and DFI &gt; 48 months (3-year OS 73.5%). <strong>Conclusions: </strong>Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT.
DOI: 10.5281/zenodo.4384601
title: Dataset related to article "Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"

description: This record contains raw data related to article “Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy" <strong>Introduction: </strong>Liver and lung are common sites of metastases from colorectal cancer (CRC). Stereotactic body radiation therapy (SBRT) represents a valid treatment, with high rates of local control (LC). In this study, we applied recursive partitioning model-based analysis (RPA) to define class risks for overall survival (OS) and progression free survival (PFS) in oligometastatic CRC patients. <strong>Materials and methods: </strong>In this monocentric analysis, we included patients with lung or liver metastases. Patients were candidate to SBRT if a maximum of 5 metastases. End points of the present analysis were LC, PFS, and OS. The binary classification tree approach with RPA was applied to stratify the patients into risk groups based on OS and PFS. <strong>Results: </strong>218 patients were treated with SBRT on 371 metastases. Majority of patients (56%) was treated on single lesion, followed by 2 (26.1%) and 3 lesions (14.7%). Median follow-up was 22.7 months. Rates of LC were 84.2% at 1 year and 73.8% at 3 years. Rates of PFS at 1 and 3 years were 42.2% and 14.9%, respectively. RPA identified 3 classes for PFS, according to age and number of metastases with 3-year PFS of 30.6%, 13.5% and 8.4%. Overall survival was 87.2% at 1 year, 51.9% at 3 years, and 36.8% at 5 years. RPA identified 3 nodes. Class 1 included patients with liver metastases (3-year OS 35.2%). Class 2 included patients with lung metastases and DFI ≤ 48 months (3-year OS 65%). Class 3 included patients with lung metastases and DFI &gt; 48 months (3-year OS 73.5%). <strong>Conclusions: </strong>Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT.
DOI: 10.5281/zenodo.4384608
title: Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity

description: <strong>Introduction: </strong>Biliary tract cancers (BTC) are rare malignancies arising from biliary system. Systemic therapy is the cornerstone for stage IV disease, with poor overall survival (OS). Evidence is lacking about safety and efficacy of local ablative treatments, such as surgery and stereotactic body radiotherapy (SBRT) in the context of metastatic BTC (mBTC). <strong>Materials and methods: </strong>We retrospectively analyzed clinical outcomes for a cohort of mBTC patients treated with SBRT for oligometastatic disease. Inclusion criteria were 1-5 distant metastases; SBRT with a dose/fraction of a least 5 Gy to a biological effective dose (BED) of at least 40 Gy considering an α/β of 10 Gy. Analyzed outcomes included local control (LC), distant progression-free survival (DPFS), PFS, and OS. <strong>Results: </strong>51 patients meeting the inclusion criteria. Primary tumor sites were intrahepatic cholangiocarcinoma (35%), extrahepatic cholangiocarcinoma (31%), ampullary adenocarcinoma (20%), gallbladder adenocarcinoma (14%). 21 patients were treated on liver lesions, 17 on nodal metastasis, 5 patients on lung lesions, 4 patients on recurrence along the extrahepatic bile duct. After a median follow-up of 14 months median OS was 13.7 months, 1- and 2-year OS were 58% and 41%, respectively. Node and lung as metastatic sites were associated with a longer OS (p &lt; 0.001). Median LC was 26.8 months, and intrahepatic cholangiocarcinoma was associated with longer LC (p = 0.036). Median DPFS was 11 months, with 1- and 2-year DPFS of 48% and 27.8%, respectively. Ten patients reported grade 1-2 toxicity and 2 cases of acute G3 biliary obstruction. <strong>Conclusions: </strong>Stereotactic body radiotherapy (SBRT) is feasible in the context of mBTC. OS and PFS results are promising, considering that our patients were heavily pre-treated with systemic therapy. Patients with nodal or lung relapse have better prognosis. Distant relapses remain the main pattern of failure, but treatment of all metastatic sites seems to improve DMFS.
DOI: 10.5519/qd.vqk25yd9
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (3 records)
DOI: 10.5281/zenodo.4384618
title: Dataset related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies"

description: This record contains raw data related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies" <strong>Aims: </strong>Bladder cancer represents the most common type of urothelial carcinoma, with a median overall survival of 12.5-15 months in the case of metastatic disease. We evaluated the role of stereotactic body radiation therapy (SBRT) in the management oligometastatic urothelial cancer. <strong>Materials and methods: </strong>Data on patients with a maximum of five metastases were collected from three institutions. Concomitant systemic therapy was allowed. End points were the local control of treated metastases, distant progression-free survival (PFS), overall PFS and overall survival. <strong>Results: </strong>Data for 82 lesions and 61 patients were included. The primary tumour was located in the bladder in 82% of patients, followed by kidney pelvis (11.5%). The most common treated site was lung (40.2%). Twenty-nine (47.5%) and 14 (23%) patients received systemic therapy before and during SBRT, respectively. The median BED10 value was 78.7 Gy. The median follow-up was 17.2 months. Rates of local control at 1 and 2 years were 92% and 88.9%, respectively, with correlation with systemic therapy before SBRT (hazard ratio 2.62, P = 0.034). Overall PFS at 1 and 2 years was 47.9% and 38.1%, respectively. The number of metastases was a predictive factor (hazard ratio 2.65, P = 0.008). The median overall survival was 25.6 months. Total dose (hazard ratio 0.93, P = 0.003) and BED10 (hazard ratio 0.97, P = 0.006) were correlated with overall survival. No grade ≥2 adverse events were reported. <strong>Conclusions: </strong>SBRT represents an effective and safe treatment in metastatic urothelial carcinoma. Prospective randomised trials are necessary to better evaluate the benefit on delaying the onset of new systemic therapies.
DOI: 10.5281/zenodo.4384617
title: Dataset related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies"

description: This record contains raw data related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies" <strong>Aims: </strong>Bladder cancer represents the most common type of urothelial carcinoma, with a median overall survival of 12.5-15 months in the case of metastatic disease. We evaluated the role of stereotactic body radiation therapy (SBRT) in the management oligometastatic urothelial cancer. <strong>Materials and methods: </strong>Data on patients with a maximum of five metastases were collected from three institutions. Concomitant systemic therapy was allowed. End points were the local control of treated metastases, distant progression-free survival (PFS), overall PFS and overall survival. <strong>Results: </strong>Data for 82 lesions and 61 patients were included. The primary tumour was located in the bladder in 82% of patients, followed by kidney pelvis (11.5%). The most common treated site was lung (40.2%). Twenty-nine (47.5%) and 14 (23%) patients received systemic therapy before and during SBRT, respectively. The median BED10 value was 78.7 Gy. The median follow-up was 17.2 months. Rates of local control at 1 and 2 years were 92% and 88.9%, respectively, with correlation with systemic therapy before SBRT (hazard ratio 2.62, P = 0.034). Overall PFS at 1 and 2 years was 47.9% and 38.1%, respectively. The number of metastases was a predictive factor (hazard ratio 2.65, P = 0.008). The median overall survival was 25.6 months. Total dose (hazard ratio 0.93, P = 0.003) and BED10 (hazard ratio 0.97, P = 0.006) were correlated with overall survival. No grade ≥2 adverse events were reported. <strong>Conclusions: </strong>SBRT represents an effective and safe treatment in metastatic urothelial carcinoma. Prospective randomised trials are necessary to better evaluate the benefit on delaying the onset of new systemic therapies.
DOI: 10.6084/m9.figshare.13502907.v1
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: EXPERIMENTAL CONDITIONS FOR ANN PREDICTION.xlsx
DOI: 10.6084/m9.figshare.13502904
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: FTIR.xlsx
DOI: 10.6084/m9.figshare.13502913
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: BET SURFACE AREA.xlsx
DOI: 10.6084/m9.figshare.13502910
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: XRD.xlsx
DOI: 10.6084/m9.figshare.13502910.v1
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: XRD.xlsx
DOI: 10.6084/m9.figshare.13502904.v1
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: FTIR.xlsx
DOI: 10.6084/m9.figshare.13502907
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: EXPERIMENTAL CONDITIONS FOR ANN PREDICTION.xlsx
DOI: 10.6084/m9.figshare.13502913.v1
title: Suplimentary materials from Removal of 4-chloro-2-methylphenoxyacetic acid from water by MIL-101(Cr) metal-organic framework: kinetics, isotherms and statistical models

description: BET SURFACE AREA.xlsx
DOI: 10.6084/m9.figshare.13502970.v1
title: Data and scripts for Figures 8 and 9 from Using adjoint-based optimization to enhance ignition in non-premixed jets

description: Data and Matlab files to reproduce Figures 8 and 9.
DOI: 10.6084/m9.figshare.13502970
title: Data and scripts for Figures 8 and 9 from Using adjoint-based optimization to enhance ignition in non-premixed jets

description: Data and Matlab files to reproduce Figures 8 and 9.
DOI: 10.6084/m9.figshare.13502973
title: Data and scripts for Figures 1 to 7 from Using adjoint-based optimization to enhance ignition in non-premixed jets

description: Data and Matlab files to reproduce Figures 1 to 7.
DOI: 10.6084/m9.figshare.13502979
title: Data and scripts for Figures 10 and 11 from Using adjoint-based optimization to enhance ignition in non-premixed jets

description: Data and Matlab files to reproduce Figures 10 and 11.
DOI: 10.6084/m9.figshare.13502979.v1
title: Data and scripts for Figures 10 and 11 from Using adjoint-based optimization to enhance ignition in non-premixed jets

description: Data and Matlab files to reproduce Figures 10 and 11.
DOI: 10.6084/m9.figshare.13502992
title: Monitor.hpp from An agent-based model of the interrelation between the COVID-19 outbreak and economic activities

description: Source code files of the simulation
DOI: 10.6084/m9.figshare.13502992.v1
title: Monitor.hpp from An agent-based model of the interrelation between the COVID-19 outbreak and economic activities

description: Source code files of the simulation